Moti Nagar will be appointed CEO of BATM instead of Zvi Marom – Techtime

by time news

October 9, 2022

Marom has managed BATM since its inception in 1992. Nagar brings expertise in the areas of accounting, day-to-day operations and mergers and acquisitions. The company’s stock lost more than 70% of its price in the last year

In the photo above: Moti Nagar (right) and Zvi Marom

CFO of a company BATM Mahod Hasharon, Moti Nagar, will assume the position of CEO of the company as of January 1, 2023. He will replace Dr. Zvi Marom, who has managed the company since its establishment in 1992. Marom will continue to serve as a member of the company’s board of directors without an active management role. Nagar joined BATM in 2014, after about a decade during which he served in management positions at Deloitte. In 2015, he was appointed to the position of CFO of the group, and for the past three years he has served as the actual operations manager of the company, assisting Marom in its day-to-day management.

The company’s chairman, Dr. Gideon Hitayit, said that Shangar brings with him financial knowledge and expertise in the field of mergers and acquisitions, “which will help shape the future of BATM as a global company.” Zvi Marom said that the group’s main areas of activity in the field of communication and cyber (Networking & Cyber) and biomedical are at a point of change. “I feel that this is the right moment to hand over the management of the team to a person who will know how to bring it to the next level.” The BATM group is based on two related and very different activities: the communication and cyber solutions group provides access solutions to communication networks in the NFV format and network monitoring tools for the purpose of detecting attacks. The biomedical division provides laboratory equipment, testing services and treatment of biological waste.

In the first half of 2022, the group’s sales totaled approximately $57.5 million: the communications and cyber division was responsible for sales amounting to $13.1 million, and the biomedical division was responsible for sales amounting to $44.4 million. Habachera is traded on the London Stock Exchange and the Tel Aviv Stock Exchange according to a market value of approximately NIS 487 million. In the past year, the company’s stock has lost more than 70% of its price: in October 2021, it was trading at a price of 378 shekels per share, and today it is trading at a price of about 110 shekels per share.

Posted in the categories: people, news, Israeli industry

Posted in tags: BATM, Batem, Zvi Marom

You may also like

Leave a Comment